Clinical and physiological responses to prolonged nasogastric administration of doxapram for apnea of prematurity.
We hypothesized that enteral doxapram would effectively treat apnea of prematurity without the appearance of major side effects. Of 16 infants, 10 (BW 1,520 +/- 102 g) received doxapram alone and 6 (BW 1,020 +/- 35 g) received doxapram plus theophylline. Apneas decreased from 16.7 +/- 1.9 to 2.1 +/- 0.6 in infants receiving doxapram alone, and from 38.2 +/- 4.4 to 7.9 +/- 2.2 apneas/24 h in those receiving doxapram plus theophylline. This was associated with an increase in alveolar ventilation, a shift of the ventilatory response to CO2 to the left, and no change in the immediate ventilatory response to 100% oxygen. Side effects included premature teeth buds corresponding to the lower central incisors, prevalence of occult blood in stool and necrotizing enterocolitis. The findings suggest that doxapram effectively controls apnea when given enterally, but should be used cautiously because of potentially harmful side effects.
Tay-Uyboco
J
J
Department of Pediatrics, University of Manitoba, Winnipeg, Canada.
Kwiatkowski
K
K
Cates
D B
DB
Seifert
B
B
Hasan
S U
SU
Rigatto
H
H
D001049:Apnea / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004315:Doxapram / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D007441:Intubation, Gastrointestinal; D008297:Male; D012129:Respiratory Function Tests; D013806:Theophylline / Q000627:therapeutic use
D004315:Doxapram; D013806:Theophylline